Últimas noticias sobre ArriVent BioPharma (NASDAQ:AVBP) Bolsa

ArriVent BioPharma

ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

ArriVent BioPharma Inc

Throughout the last three months, 5 analysts have evaluated Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Williams Companies, presenting an average target of $59.0, a high estimate of $65.00, and a low estimate of $51.00. This current average has increased by 3.96% from the previous average price target of $56.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1741114884_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Williams Companies's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$63.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Spiro Dounis</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$56.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Holly Stewart</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$51.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Williams Companies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Williams Companies compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Williams Companies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Williams Companies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WMB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Williams Companies analyst ratings.</a>
<h2>All You Need to Know About Williams Companies</h2>
Williams Companies is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
<h3>Williams Companies: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Williams Companies's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -1.47%. This indicates a decrease in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Williams Companies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.68% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Williams Companies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Williams Companies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.9%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Williams Companies's debt-to-equity ratio is below the industry average at 2.17, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 5 Analyst Projections For Williams Companies

In the preceding three months, 4 analysts have released ratings for Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $323.5, a high estimate of $350.00, and a low estimate of $305.00. Marking an increase of 3.69%, the current average surpasses the previous average price target of $312.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741114868_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Automatic Data Processing by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$324.00</td>
<td>$318.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$305.00</td>
<td>$290.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Automatic Data Processing. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Automatic Data Processing compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Automatic Data Processing's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Automatic Data Processing analyst ratings.</a>
<h2>All You Need to Know About Automatic Data Processing</h2>
Automatic Data Processing is a global technology company providing cloud-based human capital management solutions enabling clients to better implement payroll, talent, time, tax, and benefits administration. Additionally, ADP provides human resource outsourcing solutions that allow customers to offload some of their traditional HR tasks. The company operates through two segments: employer services and the professional employer organization services. Employer services consists of the company's HCM products as well as a la carte HRO solutions. PEO services contains ADP's comprehensive HRO solution where it acts as a co-employer with its customer. As of fiscal 2024, ADP serves over 1.1 million clients and pays over 42 million workers across 140 countries.
<h3>Financial Milestones: Automatic Data Processing's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Automatic Data Processing's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.49%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 20.17%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Automatic Data Processing's ROE excels beyond industry benchmarks, reaching 18.48%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.7%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.84, Automatic Data Processing adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Automatic Data Processing: Insights From 4 Analyst Reviews

Investors with a lot of money to spend have taken a bullish stance on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 12 uncommon options trades for Merck &amp; Co.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 16%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $108,276, and 9 are calls, for a total amount of $551,530.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $105.0 for Merck &amp; Co over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Merck &amp; Co's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Merck &amp; Co's whale trades within a strike price range from $80.0 to $105.0 in the last 30 days. 
<h3>Merck &amp; Co Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741114864_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$6.0</td>
<td>$5.65</td>
<td>$5.8</td>
<td>$90.00</td>
<td>$116.0K</td>
<td>10.2K</td>
<td>297</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$16.35</td>
<td>$16.15</td>
<td>$16.15</td>
<td>$80.00</td>
<td>$96.8K</td>
<td>2.9K</td>
<td>65</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$6.5</td>
<td>$6.4</td>
<td>$6.5</td>
<td>$90.00</td>
<td>$75.4K</td>
<td>10.2K</td>
<td>967</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.59</td>
<td>$1.46</td>
<td>$1.59</td>
<td>$95.00</td>
<td>$55.6K</td>
<td>5.8K</td>
<td>1.8K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$5.85</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$105.00</td>
<td>$55.2K</td>
<td>3.5K</td>
<td>119</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Following our analysis of the options activities associated with Merck &amp; Co, we pivot to a closer look at the company's own performance.
<h3>Where Is Merck &amp; Co Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 7,710,730, the MRK's price is down by -0.3%, now at $92.87. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 51 days.</li>
</ul>
<h3>Expert Opinions on Merck &amp; Co</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $108.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has decided to maintain their Market Perform rating on Merck &amp; Co, which currently sits at a price target of $96. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Merck &amp; Co, targeting a price of $112. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Merck &amp; Co, targeting a price of $115. 
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Merck &amp; Co, which currently sits at a price target of $115. 
&#x2A; Reflecting concerns, an analyst from Deutsche Bank lowers its rating to Hold with a new price target of $105.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Merck &amp; Co options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Spotlight on Merck & Co: Analyzing the Surge in Options Activity

In the last three months, 6 analysts have published ratings on Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $44.0, a high estimate of $47.00, and a low estimate of $40.00. This current average represents a 4.76% decrease from the previous average price target of $46.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1741114860_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Rexford Industrial Realty among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$47.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$41.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rexford Industrial Realty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rexford Industrial Realty compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Rexford Industrial Realty's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Rexford Industrial Realty's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/REXR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rexford Industrial Realty analyst ratings.</a>
<h2>Discovering Rexford Industrial Realty: A Closer Look</h2>
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.
<h3>Rexford Industrial Realty: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Rexford Industrial Realty's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 15.43%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 24.46%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Rexford Industrial Realty's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.74%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Rexford Industrial Realty's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.47%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Rexford Industrial Realty's debt-to-equity ratio is below the industry average. With a ratio of 0.41, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REXR

Analyst Expectations For Rexford Industrial Realty's Future

Investors with a lot of money to spend have taken a bearish stance on JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with JD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 34 uncommon options trades for JD.com.
This isn't normal.
The overall sentiment of these big-money traders is split between 32% bullish and 41%, bearish.
Out of all of the special options we uncovered, 10 are puts, for a total amount of $1,316,845, and 24 are calls, for a total amount of $1,426,507.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $37.5 to $65.0 for JD.com during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in JD.com's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to JD.com's substantial trades, within a strike price spectrum from $37.5 to $65.0 over the preceding 30 days.
<h3>JD.com Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741114859_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.85</td>
<td>$2.71</td>
<td>$2.8</td>
<td>$40.00</td>
<td>$910.0K</td>
<td>2.9K</td>
<td>3.2K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$1.76</td>
<td>$1.59</td>
<td>$1.67</td>
<td>$49.00</td>
<td>$501.0K</td>
<td>200</td>
<td>3.0K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$1.41</td>
<td>$1.34</td>
<td>$1.38</td>
<td>$42.00</td>
<td>$138.0K</td>
<td>1.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$10.45</td>
<td>$10.25</td>
<td>$10.25</td>
<td>$50.00</td>
<td>$102.5K</td>
<td>1.1K</td>
<td>101</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$7.2</td>
<td>$7.05</td>
<td>$7.15</td>
<td>$47.00</td>
<td>$71.5K</td>
<td>0</td>
<td>100</td>
</tr>
</tbody>
</table>

<h3>About JD.com</h3>
JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Having examined the options trading patterns of JD.com, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of JD.com</h3>
<ul>
<li>With a volume of 7,663,813, the price of JD is up 2.46% at $41.23. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 2 days.</li>
</ul>
<h3>Professional Analyst Ratings for JD.com</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $55.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on JD.com, which currently sits at a price target of $55. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for JD.com with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

What the Options Market Tells Us About JD.com

Deep-pocketed investors have adopted a bearish approach towards Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 100 extraordinary options activities for Boeing. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 43% leaning bullish and 45% bearish. Among these notable options, 37 are puts, totaling $5,375,352, and 63 are calls, amounting to $4,032,831.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $250.0 for Boeing during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Boeing stands at 1997.66, with a total volume reaching 28,469.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Boeing, situated within the strike price corridor from $90.0 to $250.0, throughout the last 30 days.
<h3>Boeing 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741114854_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$23.95</td>
<td>$23.1</td>
<td>$23.7</td>
<td>$170.00</td>
<td>$2.3M</td>
<td>9.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$14.15</td>
<td>$14.05</td>
<td>$14.05</td>
<td>$155.00</td>
<td>$734.7K</td>
<td>1.7K</td>
<td>14</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$42.5</td>
<td>$41.65</td>
<td>$42.5</td>
<td>$150.00</td>
<td>$425.0K</td>
<td>1.5K</td>
<td>140</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.8</td>
<td>$9.4</td>
<td>$9.5</td>
<td>$140.00</td>
<td>$380.0K</td>
<td>3.9K</td>
<td>664</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$13.9</td>
<td>$13.55</td>
<td>$13.9</td>
<td>$230.00</td>
<td>$125.1K</td>
<td>1.1K</td>
<td>128</td>
</tr>
</tbody>
</table>

<h3>About Boeing</h3>
Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and Global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with defense contractors such as Lockheed and Northrop to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
<h3>Where Is Boeing Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 10,822,445, the BA's price is down by -5.22%, now at $161.18. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 50 days.</li>
</ul>
<h3>What The Experts Say On Boeing</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $210.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Boeing, maintaining a target price of $210. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Boeing with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

A Closer Look at Boeing's Options Market Dynamics

Across the recent three months, 6 analysts have shared their insights on Montrose Environmental Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEG#NYSE">MEG</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Montrose Environmental Gr and provided 12-month price targets. The average target is $37.83, accompanied by a high estimate of $39.00 and a low estimate of $33.00. This current average represents a 6.2% decrease from the previous average price target of $40.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1741114849_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Montrose Environmental Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Michael Hoffman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Montrose Environmental Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Montrose Environmental Gr compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Montrose Environmental Gr's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Montrose Environmental Gr's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MEG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Montrose Environmental Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Montrose Environmental Gr</h2>
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.
<h3>Montrose Environmental Gr: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Montrose Environmental Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.8% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -16.38%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -6.92%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.1%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Montrose Environmental Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.63.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Montrose Environmental Gr: 6 Analysts Share Their Views

During the last three months, 8 analysts shared their evaluations of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Abbott Laboratories and provided 12-month price targets. The average target is $145.12, accompanied by a high estimate of $160.00 and a low estimate of $135.00. This current average reflects an increase of 5.45% from the previous average price target of $137.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1741114836_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Abbott Laboratories among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$154.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$158.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Lawrence Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$136.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Abbott Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Abbott Laboratories's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Abbott Laboratories's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>All You Need to Know About Abbott Laboratories</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Abbott Laboratories: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Abbott Laboratories's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.16%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Abbott Laboratories's net margin excels beyond industry benchmarks, reaching 84.1%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Abbott Laboratories's ROE excels beyond industry benchmarks, reaching 21.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Abbott Laboratories's ROA excels beyond industry benchmarks, reaching 11.85%. This signifies efficient management of assets and strong financial health.
Debt Management: Abbott Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.32.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Abbott Laboratories Stands With Analysts

In the latest quarter, 11 analysts provided ratings for Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $168.09, a high estimate of $194.00, and a low estimate of $135.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 7.9%. 
<img src="https://www.benzinga.com/files/images/story/2025/1741114822_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Chord Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Diamond</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$135.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$193.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$186.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Noah Hungness</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$138.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$158.00</td>
<td>-</td>
</tr>
<tr>
<td>Doug Leggate</td>
<td>Wolfe Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$194.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$176.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$178.00</td>
<td>$192.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$161.00</td>
<td>$168.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Chord Energy. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Chord Energy compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Chord Energy's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CHRD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Chord Energy analyst ratings.</a>
<h2>Delving into Chord Energy's Background</h2>
Chord Energy Corp is an independent exploration and production company. The company acquires, exploits, develops, and explores crude oil, natural gas, and natural gas liquids in the Williston Basin.
<h3>Breaking Down Chord Energy's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Chord Energy's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 50.79%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 14.66%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Chord Energy's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.44%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Chord Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Chord Energy's debt-to-equity ratio is below the industry average at 0.12, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHRD

The Analyst Verdict: Chord Energy In The Eyes Of 11 Experts

Ohio Republican Senator Bernie Moreno is all in with <a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets">President Trump&#8216;s tariffs</a> on auto imports from Canada and Mexico. He says they&#8217;re worth the pain on the industry because they&#8217;ll help curb the flow of undocumented migrants and illegal drugs into the U.S. 
"Trump's 100% right, and all of us should rally around his demand that our two neighbors step up," Moreno said in an interview last week, <a href="https://www.bloomberg.com/news/articles/2025-03-03/ohio-senator-says-short-term-tariff-pain-worth-it-for-autos?sref=TBDibEcD">reported</a> Bloomberg. "Until they do what they need to do, yes, am I willing to take some amount of short-term pain? Absolutely, 100%.&#8221;
Auto industry leaders have warned that the measures pose significant risks to industry profits, employment and sales as they prepare for higher costs and disruptions to their North American supply chains.
<h2 class="wp-block-heading">Auto Workers In The Buckeye State</h2>
Ohio, home to nearly 100,000 auto and related industry workers, is the largest U.S. producer of engines and the second-largest producer of transmissions. Automakers with factories in Ohio include General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>), Honda Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) and Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>). The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) is based in Ohio.
<h2 class="wp-block-heading">Trump Tariffs Take Effect</h2>
&#8220;The tariffs are all set,&#8221; Trump <a href="https://www.benzinga.com/25/03/44103406/us-stocks-futures-tumble-as-traders-await-trumps-congress-address-volatility-is-certainly-being-fed-by-trump-20-moves-says-expert">told reporters</a> on Monday afternoon, saying that there was "no room" for Canada or Mexico to negotiate further delays. &#8220;They go into effect tomorrow.&#8221;
The tariffs impose 25% duties on most Canadian and Mexican imports while raising Chinese imports to 20%. These measures apply to approximately $1.5 trillion in annual imports, signaling to markets that Trump is willing to leverage economic pressure to generate revenue and boost domestic manufacturing jobs, noted the outlet.
Read Also: <a href="https://www.benzinga.com/25/03/44102599/canadian-pm-justin-trudeau-retaliates-with-25-tariffs-on-us-goods-amid-escalating-trade-war">Canadian PM Justin Trudeau Retaliates With 25% Tariffs On US Goods Amid Escalating Trade War</a>
<h2 class="wp-block-heading">Moreno Wants To Repeal Emissions Rules</h2>
Moreno, who was a luxury car dealer in Cleveland before entering politics, recently introduced legislation backed by GM, Stellantis, and Toyota Motor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) that would repeal emissions rules and give tax breaks to car manufacturers by loosening fuel economy and clean-air regulations.
The GOP Senator, who contends that U.S. auto manufacturing has been under attack from inconsistent regulations, foreign competition and misguided federal policies, said his bill would give automakers greater flexibility and long-term stability, <a href="https://www.cleveland.com/news/2025/02/us-sen-bernie-moreno-introduces-bill-to-repeal-emissions-rules-give-tax-breaks-to-automakers.html">according</a> to Cleveland.com. 
Moreno&#8217;s bill also proposes a 200% tax deduction on autoworker wages, contingent on employers meeting specific criteria, which he argues could help offset the financial strain of tariffs.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44110685/markets-see-hardly-a-flesh-wound-so-far-but-centurys-biggest-trade-war-looms-says-bob-elliott">Markets See &#8216;Hardly A Flesh Wound&#8217; So Far, But Century&#8217;s Biggest Trade War Looms, Says Bob Elliott</a></li>
</ul>
Photo: Shutterstock

Government

Large Cap

Politics

Economics

STLA

Trump's 25% Tariffs On Auto Imports Are Worth The 'Short-Term Pain,' Says Ohio GOP Senator

On Tuesday, D Boral Capital initiated coverage on Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>), a <a href="https://www.benzinga.com/general/biotech">clinical-stage immunotherapy company.</a>
The company&#8217;s lead pipeline product, TVGN-489, is a SARS-CoV-2-specific therapy.
Tevogen&#8217;s <a href="https://tevogen.com/pipeline/" target="_blank" rel="noreferrer noopener">pipeline</a> includes preclinical programs targeting Epstein-Barr virus-associated lymphomas (TVGN -930), human papillomavirus-related cervical cancer (TVGN -920), multiple sclerosis (TVGN -601), and HPV-related mouth and throat cancer (TVGN-960).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44118144/amazon-unveils-ai-reasoning-model-for-june-2025-strengthening-aws-leadership-in-ai-innovation" rel="noreferrer noopener">Amazon To Launch AI Reasoning Model In June, Reinforcing AWS&#8217;s AI Dominance</a>
Analyst Jason Kolbert writes Tevogen stands out by developing off-the-shelf T-cell therapies that address the challenges of traditional treatments.
Its unique technology allows for large-scale production of virus-targeting T cells without gene editing, making the therapies potentially safer, more affordable, and easier to access.
Unlike many competitors relying on complex, patient-specific methods, Tevogen's approach enables broader commercial use.
D Boral Capital has initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/TVGN/analyst-ratings" rel="noreferrer noopener">price forecast of $10</a>.
Tevogen Bio, in January, received $2 million in non-dilutive grant funding from KRHP LLC (Grantor) with an additional $8 million to be contributed contingent on the Grantor&#8217;s review of the <a href="https://www.benzinga.com/pressreleases/25/01/g43286431/tevogen-bio-enters-agreement-to-receive-up-to-10-million-of-non-dilutive-grant-funding" target="_blank" rel="noreferrer noopener">company&#8217;s activities</a>.
On Monday, Tevogen Bio said it would receive the remaining $8 million in funding from the Grantor before the end of the current fiscal quarter based on the Grantor&#8217;s evaluation of the company&#8217;s progress, particularly in Tevogen Bio&#8217;s artificial <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44086628/tevogen-bio-to-receive-8-million-of-non-dilutive-grant-funding-reiterates-efficient-operations" rel="noreferrer noopener">intelligence effort,&nbsp;Tevogen.AI</a>.
The analyst says, &#8220;With key clinical readouts ahead, an emphasis on operational efficiency, and the potential for industry collaborations, Tevogen represents an emerging leader in next-generation T cell therapies.&#8221;
The analyst also adds that encouraging study results could lead to regulatory talks, new partnerships, and expanded drug approvals. Tevogen&#8217;s technology may also have potential in solid tumors and autoimmune diseases.
Price Action: TVGN stock is up 9.32% at $1.29 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44118055/jp-morgan-expects-higher-fcf-upgrades-talos-energy-price-target-amid-conservative-2025-guidance" target="_blank" rel="noreferrer noopener">JP Morgan Expects Higher FCF, Upgrades Talos Energy Price Target Amid Conservative 2025 Guidance</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

Initiation

General

Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

The cryptocurrency sector, often unified in its push against traditional financial systems, is facing a deepening rift over President Donald Trump's proposal to create a <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44114998/trumps-cabinet-holds-bitcoin-solana-ethereumbut-no-cardano-or-xrp">U.S. strategic reserve of digital assets</a>.
What Happened: Unveiled in early March, the plan as ignited fierce debate over its implications for fiscal responsibility, economic equity, and the very ethos of the crypto movement. 
As Trump's Department of Government Efficiency (DOGE), led by Elon Musk, simultaneously pursues trillions in spending cuts, the contrast between these policies has sharpened divisions within the industry, pitting advocates of government-backed crypto adoption against those wary of using public funds to prop up volatile, unproven assets.
Trump's announcement, made via Truth Social on Sunday, named five cryptocurrencies—Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), and Cardano (CRYPTO: ADAA)—as candidates for the reserve.
According to data from CoinGecko, Bitcoin surged over 20% from the previous week's lows to $92,000 by Monday, with other listed tokens also rallying sharply.
The task force, established via executive order on Trump's Inauguration Day, Jan. 20, aims to cut $1 trillion from the deficit, <a href="https://www.theguardian.com/us-news/2025/feb/18/musk-trump-interview-fox-news-sean-hannity">according </a>to Musk's statements in a Fox News interview with Sean Hannity on Feb. 25.
DOGE has already claimed $55 billion in savings by Feb. 24, per its official website, targeting programs like USAID and DEI contracts at the Treasury.
Yet, the juxtaposition of these cuts with a plan to buy cryptocurrencies—assets known for wild price swings—has fueled accusations of inconsistency. 
"The overall goal is to try to get a trillion dollars out of the deficit, and if the deficit is not brought under control, America will go bankrupt," Musk told Hannity, a stance that clashes with the reserve's potential costs.
Estimates of the reserve's price tag remain vague, but the Congressional Budget Office projects the federal deficit at $2 trillion for fiscal year 2025. 
Trump has suggested raising the debt ceiling or revaluing gold to fund the purchases, per a CBS News report from Feb. 20, but no concrete mechanism has been legislated.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44077079/analysts-doubt-us-crypto-reserve-expansion-beyond-bitcoin-cite-funding-challenges">Analysts Doubt US Crypto Reserve Expansion Beyond Bitcoin, Cite Funding Challenges</a>
What Critics Are Saying: Critics argue this could divert billions into assets that, unlike Treasury bonds, lack proven long-term value.
Trump's late Sunday pledge to stockpile Bitcoin alongside Ether, XRP, SOL and ADA led to a sharp climb in the price of Bitcoin, which peaked at $92,000 on Monday.
 However, this created a notable disparity in the CME Bitcoin futures chart, with prices jumping from a Friday close of $84,500 to a Monday opening of $95,300. 
By Tuesday afternoon in Asian markets, this gap had closed as Bitcoin retreated to $83,500, erasing the prior day's gains.
Within the crypto sector, the divide is stark. 
Proponents, including some institutional investors, hail the reserve as a validation of digital assets' role in the global economy. 
The surge in Bitcoin's value post-announcement suggests a boon for early adopters, many of whom are affluent holders. 
However, dissenters like Samson Mow, CEO of JAN3, have slammed the inclusion of altcoins like XRP and SOL, arguing it prioritizes enriching specific project founders over national interest. 
"Mow also criticized the selection of assets in the reserve, arguing it was designed to enrich specific projects rather than serve a national purpose," according to a <a href="https://x.com/dgwbirch/status/1896444932325351450">report</a>, echoing sentiments on X.
Why It Matters: This tension dovetails with DOGE's spending cuts, which have axed tens of thousands of federal jobs and shuttered agencies like the Consumer Financial Protection Bureau, per TIME's Feb. 13 overview.
The irony isn't lost on critics: a government slashing discretionary spending—$1.8 trillion in 2024, per Al Jazeera—might redirect funds to speculative assets.
"Trump has promised not to cut either Social Security or Medicare… If that promise holds, it narrows DOGE's options for cutting spending by $1 trillion," Al Jazeera <a href="https://www.aljazeera.com/news/2025/2/25/how-the-us-spends-taxpayer-money-as-musk-led-doge-seeks-cuts">noted</a>, highlighting the fiscal tightrope.
The reserve's beneficiaries, critics contend, would be a select few—namely, wealthy crypto investors—while taxpayers shoulder the risk.
Legal hurdles loom large. 
DOGE's access to Treasury data has already sparked lawsuits, with a federal judge blocking it on Feb.8 per BBC News, citing privacy concerns.
The reserve would likely require Congressional approval, a process experts deem uncertain given the GOP's slim House majority and Senate dynamics, as PBS News reported on Feb. 8.
"It's not clear how much in savings can be achieved without Congress codifying it in law," said Douglas Elmendorf, former CBO director, in the PBS piece.
What&#8217;s Next: As of today, the crypto sector remains split.
Posts on X reflect growing unease, with users like author Dave Birch questioning the reserve's intent, while market data shows holders reaping immediate gains. 
For DOGE advocates, the reserve undermines their fiscal hawkishness; for crypto idealists, it betrays the decentralized dream.
With Bitcoin hovering at $83,500 and legislative battles ahead, Trump's plan has exposed a fault line that may redefine both crypto's future and America's fiscal priorities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44105461/bitcoin-bottom-will-be-70000-at-worst-arthur-hayes-says">Bitcoin Bottom Will Be $70,000 &#8216;At Worst,&#8217; Arthur Hayes Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

$XRP

Donald Trump's Bitcoin, XRP, Cardano Reserve Proposal Drives Wedge In Crypto Industry

Management

Goldman Sachs Plans To Conduct An Annual Performance-related Review In Spring That Could Lead To Small Number Job Cuts; Goldman Sachs May Cut 3% To 5% Of Staff As Part Of Annual Review

<a href="https://www.wsj.com/politics/policy/commerce-to-overhaul-internet-for-all-plan-expanding-starlink-funding-prospects-74664efc?mod=latest_headlines" title="https://www.wsj.com/politics/policy/commerce-to-overhaul-internet-for-all-plan-expanding-starlink-funding-prospects-74664efc?mod=latest_headlines">https://www.wsj.com/politics/policy/commerce-to-overhaul-internet-for-all-plan-expanding-starlink-funding-prospects-74664efc?mod=latest_headlines</a>

'Commerce To Overhaul 'Internet For All' Plan, Expanding Starlink Funding Prospects; Agency Plans Changes That Will Make Elon Musk's Satellite-Internet Service Eligible For More Rural Broadband Funding' - WSJ

In the current market session, Realty Income Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) stock price is at $57.51, after a 0.07% drop. However, over the past month, the company's stock spiked by 7.65%, and in the past year, by 11.51%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1741113954_0.png" alt="Past Year Chart" />

<h3>Realty Income P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Realty Income has a lower P/E than the aggregate P/E of 109.64 of the Retail REITs industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1741113954_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Realty Income

JP Morgan analyst Pinjalim Bora reiterated the Neutral rating on GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>), lowering the <a target="_blank" href="https://www.benzinga.com/quote/gtlb/analyst-ratings" rel="noreferrer noopener">price forecast to $62 from $65.</a>
Yesterday, the company reported quarterly earnings of 33 cents per share, which <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44095065/gitlab-shares-rise-after-better-than-expected-q4-report-details" rel="noreferrer noopener">beat the analyst consensus estimate of 23 cents</a>. Quarterly revenue came in at $211.43 million, which beat the analyst consensus estimate of $206.12 million.
GitLab sees first-quarter adjusted earnings of between 14 cents and 15 cents per share, and revenue in a range of $212 million to $213 million.
Bora acknowledges that the fourth quarter was a strong quarter for bookings, with several growth factors continuing to contribute.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/contracts/25/03/44109280/whats-going-on-with-ionq-stock-today-6" rel="noreferrer noopener">What&#8217;s Going On With IonQ Stock Today?</a>
Meanwhile, after adjusting for the pricing benefit, which remains in the low 20s percentage-wise, the analyst writes that the current stock price reflects a &#8220;balanced risk-reward&#8221; profile.
The analyst highlights that the guidance provided assumes several factors.
First, there is no change in the guidance approach compared to FY25. Second, the guidance assumes no significant shifts in the macroeconomic environment.
Third, GitLab isn&#8217;t factoring in extra caution regarding its public sector business, which accounts for 12% of its ARR, mostly tied to the U.S. federal government.
Lastly, while GitLab exceeded its initial FY25 pricing impact estimates of $15 million &#8211; $20 million, management expects a similar revenue impact in FY26, though they haven&#8217;t specified the exact amount, Bora writes.
Price Action: GTLB shares are trading higher by 5.71% to $59.46 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44103610/taiwan-semiconductor-doubles-down-on-us-chipmaking-165-billion-investment-set-to-reshape-tech-jobs" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Doubles Down On US Chipmaking, Plans $165 Billion Investment</a></li>
</ul>
Photo by T. Schneider via Shutterstock.

Equities

Price Target

Reiteration

GTLB

GitLab's Growth Holds Steady, But Analyst Lowers Price Forecast On Cautious Outlook

On Tuesday, PepGen Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the company can review results <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44106225/pepgen-announces-update-to-phase-2-connect2-edo51-study-in-patients-with-dmd" rel="noreferrer noopener">from the 10 mg/kg cohort</a>.
The first two cohorts of the CONNECT1 study are fully enrolled and data from the 10 mg/kg cohort are expected during the third quarter of 2025. No new safety issues related to PGN-EDO51 have been observed since the company&#8217;s last safety update as of January 23, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44115317/capricor-therapeutics-cell-therapy-goes-under-priority-fda-review-for-duchenne-associated-heart-condition" rel="noreferrer noopener">Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition</a>
&#8220;With our 10 mg/kg cohort of CONNECT1 study fully enrolled and data expected later this year, we decided to pause CONNECT2 until we are able to review results from the 10 mg/kg cohort in patients with DMD. This will allow us to gather additional safety data, assess the impact of this dose of PGN-EDO51 on dystrophin levels, and potentially improve the design of CONNECT2,&#8221; said James McArthur, president and CEO of PepGen.
&#8220;This decision enables us to focus resources on completing CONNECT1, as well as rapidly advancing our FREEDOM studies in myotonic dystrophy type 1 with PGN-EDODM1, in which we recently reported encouraging initial clinical data from the Phase 1 FREEDOM-DM1 study,&#8221; McArthur added.
In February, PepGen&nbsp;announced early data&nbsp;from its FREEDOM-DM1 trial <a target="_blank" href="https://www.benzinga.com/news/25/02/43918260/why-pepgen-pepg-stock-is-skyrocketing-today" rel="noreferrer noopener">for myotonic dystrophy</a>.
The study showed significant dose-dependent splicing correction, with mean corrections of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.
Price Action: PEPG stock is down 21% at $2.22 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44117280/genius-sports-q4-results-sales-jump-margins-expand-more" target="_blank" rel="noreferrer noopener">Genius Sports Q4 Results: Sales Jump, Margins Expand &amp; More</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.com

PEPG

PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls

A high-stakes deal that could have reshaped global supply chains has crumbled. The negotiations between US President Donald Trump and Ukrainian President Volodymyr Zelenskyy were meant to secure a partnership granting the US priority access to Ukraine's vast reserves of critical minerals &#8211; resources vital for military technology, electric vehicles (EVs) and advanced electronics. 
However, the talks unraveled over security concerns and shifting priorities, leaving both nations scrambling for alternatives. Now, the fallout is poised to send ripples through markets, affecting stocks and <a href="https://www.benzinga.com/etfs">ETFs linked to these key industries</a>. Investors should closely monitor the funds and equities most exposed to this disruption.
Also Read: <a href="https://www.benzinga.com/25/03/44064817/zelenskyy-says-not-sure-he-did-something-bad-after-public-spat-with-trump-jd-vance-we-have-to-be-very-honest-and-direct">Zelenskyy Says &#8216;Not Sure&#8217; He Did Something Bad After Public Spat With Trump, JD Vance: &#8216;We Have To Be Very Honest And Direct&#8217;</a>
ETFs In The Spotlight
With the deal off the table, ETFs tracking rare earth minerals, defense and EV industries could see increased volatility:
VanEck Rare Earth/Strategic Metals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REMX#NYSE">REMX</a>): Holds stocks involved in rare earth mining and processing, sectors now facing renewed uncertainty. Pilbara Minerals Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) and Arcadium Lithium Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) are among its top holdings.
Global X Lithium &amp; Battery Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LIT#NYSE">LIT</a>): Focuses on lithium and battery-related companies, which depend on stable mineral supplies. The fund has allocated its assets to companies like Mineral Resources, Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>).
iShares US Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>): Tracks major defense contractors like Raytheon Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) and Northrop Grumman Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), that may face cost pressures due to supply chain disruptions. 
What Was At Stake?
The abandoned agreement would have given the US <a href="https://www.benzinga.com/25/02/43968607/trump-negotiates-a-very-big-deal-for-ukraines-mineral-wealth">priority access to Ukraine's reserves of critical minerals</a> essential for military technology, EVs and advanced electronics. In return, Ukraine expected a financial boost, with 50% of state-owned mineral revenues going into an investment fund for economic recovery. However, without US security guarantees, Ukraine hesitated to finalize the deal, ultimately leading to its collapse.
With no agreement in place, both the US and Ukraine face economic and strategic setbacks. The US remains reliant on China for rare earth processing, while Ukraine may now seek alternative partnerships—potentially with China or European nations.
Also Read: <a href="https://in.benzinga.com/news/25/02/43974696/mark-cuban-surprisingly-loves-the-trump-administrations-push-for-ukrainian-rare-minerals-heres-why-he-thinks-its-good-for-both-sides">Mark Cuban Surprisingly &#8216;Loves&#8217; The Trump Administration&#8217;s Push For Ukrainian Rare Minerals—Here&#8217;s Why He Thinks It&#8217;s Good For Both Sides</a>
US Defense And Tech Stocks
The US defense and tech industries are major consumers of rare earth minerals. Companies like Lockheed Martin, Northrop Grumman and Raytheon Technologies rely on these materials for advanced weaponry and aerospace systems. The lack of a stable mineral supply chain outside China could make sourcing components more expensive, potentially affecting these stocks.
Semiconductor giants like NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) could also see cost pressures, as rare earth elements are crucial for chip production. If US companies must continue depending on China for processing, it could impact supply chain stability and pricing.
Lithium and rare earth mining companies like MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>), which processes rare earths domestically, might see increased interest as the US looks to expand its refining capabilities.
What's Next?
With the US unable to secure a direct supply of Ukrainian minerals for now, Washington may have to fast-track domestic refining projects or seek alternative deals. Meanwhile, Ukraine might turn to European nations or even China to fill the gap. For now, investors should brace for potential market fluctuations in defense, tech and EV sectors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44113716/top-5-etfs-that-defied-februarys-market-turmoil">Top 5 ETFs That Defied February&#8217;s Market Turmoil</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Broad U.S. Equity ETFs

ETFs

ALTM

INTC

iShares Dow Jones US Aerospace & Defense Index Fund

NVDA

Market Vectors Rare Earth/Strategic Metals Etf

REMX

TSLA

Broken Deal, Big Consequences: How ETFs And Stocks Will React

On Monday, Pliant Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) <a href="https://www.benzinga.com/general/biotech">announced the discontinuation</a> of the BEACON-IPF Phase 2b trial, which evaluated bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).
The move follows a prespecified data review and recommendation by the trial&#8217;s independent Data Safety Monitoring Board and a secondary review and recommendation by an <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44088147/pliant-therapeutics-stock-sinks-discontinues-mid-stage-study-for-lung-disorder" rel="noreferrer noopener">outside expert panel</a>.
Needham downgraded Pliant Therapeutics, citing no meaningful catalysts or upside drivers over the next year.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44116110/mdjms-uk-subsidiary-launches-handcrafted-goods-platform-shares-surge" rel="noreferrer noopener">MDJM Debuts Its E-Commerce Platform: Details</a>
Needham analyst Joseph Stringer writes that the IPF program was the main value driver for Pliant Therapeutics.
The remainder of the pipeline is relatively thin and in early-stage development.
Needham has downgraded from Buy to Hold, with no price target assigned compared to $10 previously.
With the stopped IPF program, the update has created a significant challenge if the drug is considered for other conditions.
Pliant Therapeutics notes that bexotegrast showed some effectiveness in the IPF trial, leaving room for potential dose-ranging studies to improve its benefit-risk profile—possibly even in IPF again.
However, this would be a long and difficult process with uncertain prospects. Bexotegrast has also shown promise in primary sclerosing cholangitis (<a href="https://publications.ersnet.org/content/erj/64/suppl68/oa2861" target="_blank" rel="noreferrer noopener">PSC</a>), but its development in this condition carries risks.
Price Action: PLRX stock is up 0.36% at $1.38 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44118489/starbucks-brews-a-new-cfo-taps-nordstrom-executive-cathy-smith-amid-organizational-changes" target="_blank" rel="noreferrer noopener">Starbucks Brews A New CFO: Taps Nordstrom Executive Cathy Smith Amid Organizational Changes</a></li>
</ul>
Photo: Shutterstock

Downgrades

PLRX

Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future

<a href="https://www.wsj.com/finance/goldman-sachs-to-target-vice-presidents-in-next-round-of-cuts-9f435590?mod=latest_headlines" title="https://www.wsj.com/finance/goldman-sachs-to-target-vice-presidents-in-next-round-of-cuts-9f435590?mod=latest_headlines">https://www.wsj.com/finance/goldman-sachs-to-target-vice-presidents-in-next-round-of-cuts-9f435590?mod=latest_headlines</a>

'Goldman Sachs To Target Vice Presidents In Next Round Of Cuts; Employees Likely To Be Laid Off In Annual Culling Were Given Hints In The Form Of Small Bonuses' - WSJ

Press Releases

ArriVent Appoints Kristine Peterson to its Board of Directors

Earnings

ArriVent BioPharma Reports First Quarter 2024 Financial Results

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Comments

ArriVent BioPharma

Noticias

Últimas noticias sobre ArriVent BioPharma (NASDAQ:AVBP) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL